C

ome Friday morning, Amgen will reveal whether its costly, much-discussed new cholesterol drug will live up to blockbuster expectations — or become a cautionary tale in biopharma lore.

At the American Cardiology Conference in Washington, D.C., Amgen will present results from a 27,000-patient study determining whether its drug can reduce patients’ risk of heart attack and stroke, with sweeping ramifications for payers, patients, investors, and pharma.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • My cholesterol in September of 2016 was 240 and my LDL was 167 and here in March of 2017 after only 3 injections of Praluent 75 mg. My cholesterol is now 114 and my LDL is 37. Pretty amazing

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.